title: Potentiating antitumor immunity with αGC-loaded exosomes.
abstract: Anticancer immunotherapy is a promising treatment modality since it bears the potential of being highly specific, but effective clinical applications are still under development. We have recently described an exosome-based strategy for co-delivery of α-galactosylceramide and a tumor-associated antigen that synergistically potentiates tumor-specific adaptive immune responses while preventing the anergy of invariant natural killer T (iNKT) cells. We propose that the next generation of exosome-based immunotherapies should involve iNKT-cell ligands to induce a broad, amplified and sustainable antitumor immune response.
authors.affiliation: Translational Immunology Unit; Department of Medicine; Solna, Karolinska Institutet; Stockholm, Sweden.
authors.forename: Ulf
authors.initials: U
authors.lastname: Gehrmann
authors.affiliation: Translational Immunology Unit; Department of Medicine; Solna, Karolinska Institutet; Stockholm, Sweden.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Hiltbrunner
authors.affiliation: Translational Immunology Unit; Department of Medicine; Solna, Karolinska Institutet; Stockholm, Sweden.
authors.forename: Tanja I
authors.initials: TI
authors.lastname: Näslund
authors.affiliation: Translational Immunology Unit; Department of Medicine; Solna, Karolinska Institutet; Stockholm, Sweden.
authors.forename: Susanne
authors.initials: S
authors.lastname: Gabrielsson
keywords: bone marrow-derived dendritic cells; exosomes; invariant natural killer T cells; ovalbumin; α-galactosylceramide